vimarsana.com

Page 238 - ஆரோக்கியம் பராமரிப்பு ஆம்ப் மருத்துவமனைகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Sosei Heptares and PharmEnable Enter Technology Collaboration for AI-driven Drug Discovery against Challenging GPCR Target

Share this article Share this article TOKYO and CAMBRIDGE, England, Jan. 12, 2021 /PRNewswire/  Sosei Group Corporation ( the Company ) (TSE: 4565) and PharmEnable, a UK drug discovery company, announce they have entered a collaboration to apply their respective technologies to drive novel drug discovery against a challenging G protein-couple receptor (GPCR) target associated with neurological diseases. The collaboration will combine Sosei Heptares world-leading GPCR-focused structure-based drug design platform, which has fully structurally enabled the GPCR target, providing detailed structural insights and an assessment of tractability, with PharmEnable s proprietary advanced artificial intelligence (AI)-enabled and medicinal chemistry technologies (ChemUniverse and ChemSeek) to identify novel, highly specific drug leads for further development.

Medivir presents MIV-818 data at ASCO Gastrointestinal Cancers Symposium

Share this article STOCKHOLM, Jan. 12, 2021 /PRNewswire/ Medivir AB (Nasdaq Stockholm: MVIR) today announces that a presentation entitled Phase I study of the novel pro-drug MIV-818 in patients with hepatocellular carcinoma, intra-hepatic cholangiocarcinoma or liver metastases will be given by Professor Jeff Evans, Director of Institute of Cancer Sciences at University of Glasgow, at the virtual ASCO Gastrointestinal Cancers Symposium (ASCO-GI). The presentation will be given on January 15, 2021, at 2 pm CET during the Hepatobiliary Cancer session (presentation number 309).  The results from the completed phase Ia intra-patient dose escalation part of the study show that MIV-818 has an acceptable safety and tolerability profile and a selective effect on liver cancer cells. The inter-patient dose escalation phase Ib part is currently ongoing at a dose of 40 mg for 5 days in 21-day cycles. 

CES 2021 Taiwanese Startup iPreg s Sperm Sorting Chip is the Game-Changer in IVF Market

Share this article Share this article TAIPEI, Jan. 12, 2021 /PRNewswire/  iPreg Incorporation delivers Sperm Sorting Chip that is expected to increase fertility rate and fill in the insufficient spot within In Vitro Fertilization (IVF) process. It can replace the traditional technique of sperm isolation to boost the success rate of pregnancy upon the current IVF procedure. iPreg Inc. is a global biomedical device manufacturer in the field of reproductive medicine. Its main services focus on in vitro fertilization market and continuously improve the new generation of sperm sorting methods.  Pregnancy is not as easy as you thought. The current infertility rate is approximately 15% globally, IVF is the most efficient solution on the market with the ability to increase the pregnancy rate to 37.4%. One of the weaknesses of IVF is inefficient sperm selection with the traditional sperm sorting processes. In fact, this traditional method cannot avoid DNA fragmentation in sperm an

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.